Commercialization & Market Access
The full commercial arc for novel diagnostics.
From clinical evidence and payer strategy through commercial infrastructure and enterprise contracting, DMC works as an extension of the commercial team for diagnostic innovators.
Capabilities
Where DMC engages across the launch arc.
- 01
Laboratory Commercialization
Launch strategy for new assays, from clinical value proposition through enterprise deployment. - 02
Business Development
Enterprise selling, health-system contracting, and channel partnerships that get novel diagnostics into routine use. - 03
Diagnostic Strategy
Portfolio strategy, evidence roadmaps, and competitive positioning grounded in payer and health-system economics. - 04
Payer & coverage strategy
Coverage dossiers, MolDX-related submissions where applicable, KOL engagement, and evidence generation planning. Coverage outcomes are determined by payers, not by strategy alone. - 05
Sales enablement
Playbooks, target lists, pricing frameworks, and RFP support built for diagnostic sales cycles.
Who we serve
Innovators bringing new diagnostics to market.
Molecular diagnostics
Oncology, hereditary, infectious disease, and pharmacogenomic assay developers.
Medical device
IVD and point-of-care manufacturers requiring health-system and reference laboratory adoption.
Biotechnology
Companion diagnostic strategy and commercial infrastructure for therapeutic pipelines.
Begin the conversation